For one of the most prevalent a specific symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized...
Read MoreIn an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Read MoreResults of a Spanish two-center study suggest that low doses of rituximab are equally effective as high doses, but have a superior safety profile. The anti-CD20 monoclonal antibody rituximab is not registered for the treatment...
Read More
Only a few weeks prior to MSVirtual2020, the fully human anti-CD20 monoclonal antibody ofatumumab...
Read More
The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research...
Read More
Safety modeling favors ozanimod Patients diagnosed with multiple sclerosis appear to have fewer...
Read More
Thyroid AEs did not diminish alemtuzumab efficacy Adverse thyroid events occur frequently among...
Read More
Benefit observed in patients with or without disease activity Among multiple sclerosis patients...
Read More
Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined...
Read More
MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis...
Read More
New efficacy and safety data on ofatumumab (Kesimpta), the first and only self-administered,...
Read More
Health Union has been accepted to present research, in the form of two poster presentations,...
Read More
This year, MSVirtual2020 (ACTRIMS/ECTRIMS) congress will feature new data relating to tolebrutinib...
Read More
Download the MSVirtual2020 Program at a Glance schedule (PDF)
Read More
